[go: up one dir, main page]

BR9808770A - Conjugado medicamentoso, método para suaprodução e seu uso - Google Patents

Conjugado medicamentoso, método para suaprodução e seu uso

Info

Publication number
BR9808770A
BR9808770A BR9808770-3A BR9808770A BR9808770A BR 9808770 A BR9808770 A BR 9808770A BR 9808770 A BR9808770 A BR 9808770A BR 9808770 A BR9808770 A BR 9808770A
Authority
BR
Brazil
Prior art keywords
production
drug conjugate
conjugates
relates
enantiomer
Prior art date
Application number
BR9808770-3A
Other languages
English (en)
Inventor
Hannsj Rg Sinn
Hans-Herman Schrenk
Wolfgang Maier-Borst
Va Frei
Gerd Stehle
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of BR9808770A publication Critical patent/BR9808770A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • Y10S530/816Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"CONJUGADO MEDICAMENTOSO, MéTODO PARA SUAPRODUçãO E SEU USO". A invenção se relaciona a conjugadoscompreendendo um D-enantiómero de um antagonista de ácidofólico e um portador. A invenção também se relaciona a produçãode tais conjugados e ao uso dos mesmos.
BR9808770-3A 1997-05-09 1998-05-08 Conjugado medicamentoso, método para suaprodução e seu uso BR9808770A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97107657A EP0879604B1 (de) 1997-05-09 1997-05-09 Konjugat, umfassend einen Folsäureantagonisten und einen Träger
PCT/EP1998/002701 WO1998051349A1 (de) 1997-05-09 1998-05-08 Konjugat, umfassend einen folsäureantagonisten und einen träger

Publications (1)

Publication Number Publication Date
BR9808770A true BR9808770A (pt) 2001-10-30

Family

ID=8226780

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808770-3A BR9808770A (pt) 1997-05-09 1998-05-08 Conjugado medicamentoso, método para suaprodução e seu uso

Country Status (14)

Country Link
US (1) US6720304B1 (pt)
EP (1) EP0879604B1 (pt)
JP (1) JP2002501512A (pt)
KR (1) KR100596940B1 (pt)
CN (1) CN1260725A (pt)
AT (1) ATE236657T1 (pt)
AU (1) AU733885B2 (pt)
BR (1) BR9808770A (pt)
CA (1) CA2289448A1 (pt)
DE (1) DE59709788D1 (pt)
DK (1) DK0879604T3 (pt)
ES (1) ES2197265T3 (pt)
RU (1) RU2205662C2 (pt)
WO (1) WO1998051349A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4949557B2 (ja) * 1999-03-17 2012-06-13 ノヴォ ノルディスク アー/エス ペプチドのアシル化方法及び新規アシル化剤
US7273921B2 (en) * 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
ATE483476T1 (de) * 2003-03-20 2010-10-15 Nippon Kayaku Kk Micellen-zubereitung mit schwer wasserlöslichem anti-krebsmittel und neuem blockcopolymer
DE102004016355A1 (de) 2004-04-02 2005-11-03 Rösner Research GmbH & Co.KG Herstellung und Verwendung des Konjugats Methotrexat-Albumin als Mittel zur Immunosuppression bei GVHD
BRPI0515573A (pt) * 2004-09-22 2008-07-29 Nippon Kayaku Kk copolìmero por blocos, preparação de micela e agente anticáncer contendo a mesma como o ingrediente ativo
DE102004057196A1 (de) * 2004-11-26 2006-06-01 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Konjugaten mit Nicht-steroidalen Antirheumatika (NSAR)
AU2007252678A1 (en) * 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of podophyllotoxin
WO2008041610A1 (fr) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Mélange d'un dérivé de résorcinol avec un polymère
EP2080779B1 (en) * 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
EP2206502B1 (en) 2007-09-28 2018-09-12 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of steroid
KR101589582B1 (ko) * 2008-03-18 2016-01-28 니폰 가야꾸 가부시끼가이샤 생리활성물질의 고분자량 결합체
US9149540B2 (en) * 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
WO2010085717A1 (en) * 2009-01-24 2010-07-29 Syntrix Biosystems, Inc. Pharmaceutical composition comprising racemic aminopterin
EP2431403B1 (en) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymer conjugate of bioactive substance having hydroxy group
CA2784826A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
CN102451301A (zh) * 2010-10-22 2012-05-16 王京姝 一种治疗牛皮癣的外用膏剂
CA2816997A1 (en) 2010-11-17 2012-05-24 Nippon Kayaku Kabushiki Kaisha Novel polymer derivative of cytidine metabolic antagonist
BR112014005452B1 (pt) 2011-09-11 2021-03-16 Nippon Kayaku Kabushiki Kaisha método de produção de copolímero de bloco
RU2497825C1 (ru) * 2012-07-03 2013-11-10 Государственное Научное Учреждение "Институт Физики Имени Б.И. Степанова Национальной Академии Наук Беларуси" Конъюгат фолиевой кислоты и способ его получения
DE102017204850A1 (de) * 2017-03-22 2018-09-27 Michael Denck HSA-Konjugat

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
AU3665293A (en) * 1992-02-14 1993-09-03 Merck & Co., Inc. Chimeric toxins binding to the GnRH receptor
DE4433890C2 (de) * 1994-09-22 1999-02-18 Deutsches Krebsforsch Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
RU2071351C1 (ru) * 1996-07-23 1997-01-10 Московский научно-исследовательский институт медицинской экологии КОНЪЮГАТЫ БИОЛОГИЧЕСКИ АКТИВНЫХ ВЕЩЕСТВ С α -ФЕТОПРОТЕИНОМ, ОБЛАДАЮЩИЕ ИЗБИРАТЕЛЬНЫМ ДЕЙСТВИЕМ ПО ОТНОШЕНИЮ К РАКОВЫМ ОПУХОЛЯМ, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ

Also Published As

Publication number Publication date
KR100596940B1 (ko) 2006-07-07
CA2289448A1 (en) 1998-11-19
JP2002501512A (ja) 2002-01-15
AU7910998A (en) 1998-12-08
WO1998051349A1 (de) 1998-11-19
KR20010012412A (ko) 2001-02-15
EP0879604B1 (de) 2003-04-09
AU733885B2 (en) 2001-05-31
US6720304B1 (en) 2004-04-13
ES2197265T3 (es) 2004-01-01
RU2205662C2 (ru) 2003-06-10
CN1260725A (zh) 2000-07-19
ATE236657T1 (de) 2003-04-15
DE59709788D1 (de) 2003-05-15
EP0879604A1 (de) 1998-11-25
DK0879604T3 (da) 2003-08-04

Similar Documents

Publication Publication Date Title
BR9808770A (pt) Conjugado medicamentoso, método para suaprodução e seu uso
BR9810802B1 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto.
UY26495A1 (es) " derivados de tiazolilamida"
EE200000320A (et) Uudsed ühendid
SE9704544D0 (sv) Novel compounds
BR9909925B1 (pt) derivados de quinolina, composições farmacêuticas, e, processo para a fabricação de derivados de quinolina.
BR0009083B1 (pt) derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
BR9808422B1 (pt) composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
SE9704546D0 (sv) Novel compounds
BR9801533A (pt) Composição de uréia substituída com éter n,n,n'-trimetil-bis (aminoetila) para a produção de poliuretanos
DE59005313D1 (de) 2-Methyl- und 2-Hydroxymethyl-serin-N,N-diessigsäure und ihre Derivate.
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
BR9805437A (pt) Derivados de benzocicloalquenos heterocìclicos, processo para fabricação de derivados de benzocicloalquenos heterocìclicos e uso de derivados de benzocicloalquenos heterocìclicos.
BR0211250A (pt) Formulação amorfa, liofilizada, estável, parenteral, formulação farmacêutica, uso da mesma, artigo de manufatura, e, processo para preparar uma formulação
AR023506A1 (es) Proceso para la preparacion de pirimidinas sustituidas.
ATE87905T1 (de) Anticonvulsive agenzien.
ITMI20001848A0 (it) Faramaci per l'incontinenza.
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
NO971604L (no) Orale sabeluzolsuspensjoner
DE60029979D1 (de) LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT
BR9903115A (pt) Derivados de acridina
BR0114459A (pt) Derivados substituìdos de 5-amino-1-penten-3-ol substituidos
BR9803237B1 (pt) derivados de uréia, composição farmacêutica e processo para sua preparação.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO, ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/64 (2017.01), A61K 47/60 (2017.0